RxDoctor Payments Data

Kristerpher Brimberry

Psychiatric/Mental Health · Poplar Bluff, MONPI 1871180265

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $49,380 of the $74,476 with a category attached, or 66.3%. 12 manufacturers reported payments, led by AbbVie at 57.8% of the total. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$74,476in general payments, 2019–2025

Across 308 payments — averaging $241.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$43K
  • E.r. Squibb & Sons, L.L.C.$27K
  • Alkermes, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$789
  • Johnson & Johnson$510
  • Teva Pharmaceuticals USA, Inc.$471
  • plus $889 from 6 others

What the payments were for

  • Consulting fees$10,32014%
  • Speaking & faculty fees$49,38066%
  • Travel & lodging$7,61510%
  • Food & beverage$6,9119%
  • Education$2490%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,476 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate88$284,651
VraylarCariprazine Hcl97$137,451
RexultiBrexpiprazole44$67,571
CaplytaLumateperone Tosylate16$27,507
TrintellixVortioxetine Hydrobromide33$21,163
Chlorpromazine Hcl42$13,167
Lurasidone Hcl76$9,974
Paliperidone ErPaliperidone82$9,851
Aripiprazole191$9,087
Quetiapine Fumarate ErQuetiapine Fumarate75$7,306
Trazodone Hcl373$6,413
Hydroxyzine Pamoate230$4,492
Duloxetine Hcl178$4,253
Venlafaxine Hcl ErVenlafaxine Hcl125$3,653
Olanzapine122$2,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$510$284,65188 claims
AbbVieVraylar$43,015$137,45197 claims
Otsuka America Pharmaceutical, Inc.Rexulti$789$67,57144 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$243$27,50716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Poplar Bluff

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →